Histamine H1 receptors in patients with Alzheimer's disease assessed by positron emission tomography

Neuroscience

Volumn 99, Issue 4, 2000, Pages 721-729

  Higuchi, M ^a   Yanai, K ^a   Okamura, N ^a   Meguro, K ^a   Arai, H ^a   Itoh, M ^b   Iwata, R ^b   Ido, T ^b   Watanabe, T ^a   Sasaki, H ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Aging; Alzheimer's disease; Cognition; Histamine H1 receptors; Mini Mental State Examination; Positron emission tomography

Indexed keywords

DOXEPIN; HISTAMINE H1 RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BRAIN BLOOD FLOW; CEREBELLUM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FRONTAL LOBE; HUMAN; MALE; NERVE DEGENERATION; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; TEMPORAL LOBE;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; BRAIN CHEMISTRY; CARBON RADIOISOTOPES; CEREBROVASCULAR CIRCULATION; COGNITION; DOXEPIN; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; RECEPTORS, HISTAMINE H1; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034706072     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00230-X     Document Type: Article

References (58)

1. Airaksinen M.S., Paetau A., Paljarvi L., Reinikainen K., Riekkinen P., Suomalainen R., Panula P. Histamine neurons in human hypothalamus: anatomy in normal and Alzheimer diseased brains. Neuroscience. 44:1991;465-481.
2. Airaksinen M.S., Reinikainen K., Riekkinen P., Panula P. Neurofibrillary tangles and histamine-containing neurons in Alzheimer hypothalamus. Agents Actions. 33:1991;104-107.
3. Cacabelos R., Alvarez X.A. Histidine decarboxylase inhibition induced by α-fluoromethylhistidine provokes learning-related hypokinetic activity. Agents Actions. 33:1991;131-134.
4. Cacabelos R., Yamatodani A., Niigawa H., Hariguchi S., Tada K., Nishimura T., Wada H., Brandeis L., Pearson J. Brain histamine in Alzheimer's disease. Meth. Find. exp. clin. Pharmac. 11:1989;353-360.
5. 3H]acetylcholine from slices of rat entorhinal cortex: evidence for the possible existence of H3 receptor subtypes. Br. J. Pharmac. 107:1992;919-923.
6. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience. 19:1986;1-28.
7. Cutler N.R., Haxby J.V., Duara R., Grady C.L., Kay A.D., Kessler R.M., Sundaram M., Rapoport S.I. Clinical history, brain metabolism, and neuropsychological function in Alzheimer's disease. Ann. Neurol. 18:1988;298-309.
8. De Almeida M.A., Izquierdo I. Intracerebroventricular histamine, but not 48/80, causes posttraining memory facilitation in the rat. Arch. int. Pharmacodyn. Thér. 291:1988;202-207.
9. 2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J. cereb. Blood Flow Metab. 8:1989;696-708.
10. Friston K.J., Holmes A.P., Worsley K.J., Poline J.P., Frith C.D., Frackowiak R.S.J. Statistical parametric maps in functional imaging: a general linear approach. Human Brain Mapping. 2:1995;189-210.
11. Frost J.J. Imaging neuronal biochemistry by emission computed tomography: focus on neuroreceptors. Trends pharmac. Sci. 7:1986;490-496.
12. Fujiwara T., Watanuki S., Yamamoto S., Miyake M., Seo S., Itoh M., Ishii K., Orihara H., Fukuda H., Datoh T., Kitamura K., Tanaka K., Takahashi S. Performance evaluation of a large axial field-of-view PET scanner: SET-2400W. Ann. nucl. Med. 11:1997;307-313.
13. Higuchi M., Arai H., Okamura N., Tashiro M., Matsui T., Higuchi S., Matsushita S., Sasaki H. Apolipoprotein E and Alzheimer's disease: Therapeutic implications. CNS Drugs. 11:1999;411-420.
14. 11C]doxepin. In Quantitative Functional Brain Imaging with Positron Emission Tomography (eds Carson R., Daube-Witherspoon M. E. and Herscovitch P.), Chapter 31. Academic, San Diego, CA.
15. Holman B.L., Gibson R.E., Hill T.C., Eckelman W.C., Albert M., Reba R.C. Muscarinic acetylcholine receptors in Alzheimer's disease. In vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography. J. Am. med. Ass. 254:1985;3063-3066.
16. Huston J.P., Wagner U., Hasenöhrl R.U. The tuberomammillary nucleus projections in the control of learning, memory and reinforcement processes: evidence for an inhibitory role. Behav. Brain Res. 83:1997;97-105.
17. Inoue I., Yanai K., Kitamura D., Taniuchi I., Kobayashi T., Watanabe T., Watanabe T. Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc. natn. Acad. Sci. USA. 93:1996;13,316-13,320.
18. 11C]pyrilamine. Tohoku J. exp. Med. 178:1996;129-136.
19. Iyo M., Namba H., Fukushi K., Shinotoh H., Nagatsuka S., Suhara T., Sudo Y., Suzuki K., Irie T. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet. 349:1997;1805-1809.
20. Jones T. The role of positron emission tomography within the spectrum of medical imaging. Eur. J. nucl. Med. 23:1996;207-211.
21. Kamei C., Chung Y.H., Tasaka K. Influence of certain H1-blockers on the stp-through active avoidance response in rats. Psychopharmacology. 102:1990;312-318.
22. Kamei C., Tasaka K. Effect of histamine on memory retrieval in old rats. Biol. Pharmaceut. Bull. 16:1993;128-132.
23. Khateb A., Fort P., Pegna A., Jones B.E., Muhlethaler M. Cholinergic nucleus basalis neurons are excited by histamine in vitro. Neuroscience. 69:1995;495-506.
24. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage. 4:1996;153-158.
25. Lin J.S., Hou Y., Sakai K., Jouvet M. Histaminergic descending inputs to the mesopontine tegmentum and their role in the control of cortical activation and wakefulness in the cat. J. Neurosci. 16:1996;1523-1537.
26. Lin J.S., Sakai K., Jouvet M. Evidence for histaminergic arousal mechanisms in the hypothalamus of cat. Neuropharmacology. 27:1988;111-122.
27. 11C-methyl]-(-)-cocaine PET studies in human subjects. J. cereb. Blood Flow Metab. 10:1990;740-747.
28. Malec J. F., Ivnik R. J. and Smith G. E. (1993) Neuropsychology and normal aging: the clinician's perspective. In Neuropsychology of Alzheimer's Disease and Other Dementias (eds Parks R. W., Zec R. F. and Wilson R. S.), Part I, Chapter 2. Oxford University Press, NY.
29. Mazurkiewicz-Kwilecki I.M., Nsonwah S. Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients. Can. J. Physiol. Pharmac. 67:1989;75-78.
30. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 34:1984;939-944.
31. Meguro K., Yanai K., Sakai N., Sakurai E., Maeyama K., Fukuda H., Sasaki H., Watanabe T. Effects of thioperamide, a histamine H3 antagonist, on the step-through passive avoidance response and histidine decarboxylase activity in senescence-accelerated mice (SAM). Pharmac. Biochem. Behav. 50:1995;321-325.
32. Morisset S., Traiffort E., Schwartz J.C. Inhibition of histamine versus acetylcholine metabolism as a mechanism of tacrine activity. Eur. J. Pharmac. 315:1996;R1-R2.
33. Nakamura S., Takemura M., Ohnishi K., Suenaga T., Nishimura M., Akiguchi I., Kimura J., Kimura T. Loss of large neurons and occurrence of neurofibrillary tangles in the tuberomammillary nucleus of patients with Alzheimer's disease. Neurosci. Lett. 151:1993;196-199.
34. Nicholson A.N., Pascoe P.A., Turner C., Ganellin C.R., Greengrass P.M., Casy A.F., Mercer A.D. Sedation and histmine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br. J. Pharmac. 104:1991;270-276.
35. Nolen T.M. Sedative effects of antihistamines: safety, performance, learning, and quality of life. Clin. Therapeut. 19:1997;39-55.
36. Nordberg A. Clinical studies in Alzheimer patients with positron emission tomography. Behav. Brain Res. 57:1993;215-224.
37. Okamura N., Yanai K., Higuchi M., Sakai J., Iwata R., Ido T., Sasaki H., Watanabe T., Itoh M. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br. J. Pharmac. 129:2000;115-123.
38. Oken R.J. Antihistamines, a possible risk factor for Alzheimer's disease. Med. Hypotheses. 44:1995;47-48.
39. Onodera K., Yamatodani A., Watanabe T., Wada H. Neuropharmacology of the histamienrgic neuron system in the brain and its relationship with behavioral disorders. Prog. Neurobiol. 42:1994;685-702.
40. Panula P., Yang H.Y.T., Costa E. Histamine-containing neurons in the rat hypothalamus. Proc. natn. Acad. Sci. USA. 81:1984;2572-2576.
41. Panula P., Rinne J., Kuokkanen K., Eriksson K.S., Sallmen T., Kalimo H., Relja M. Neuronal histamine deficit in Alzheimer's disease. Neuroscience. 82:1998;993-997.
42. Passani M.B., Blandina P. Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: a parallel story. Meth. Find. exp. clin. Pharmac. 20:1998;725-733.
43. Perry E.K. The cholinergic hypothesis - ten years on. Br. Med. Bull. 42:1986;63-69.
44. Prell G.D., Khandelwal J.K., Burns R.S., LeWitt P.A., Green J.P. Elevated levels of histamine metabolites in cerebrospinal fluid of aging, healthy humans. Comp. Geront. A2:1988;114-119.
45. 3H]glycogen hydrolysis. Molec. Pharmac. 20:1981;331-338.
46. Sakai N., Sakurai E., Sakurai E., Yanai K., Miura Y., Watanabe T. Depletion of brain histamine induced by α-fluoromethylhistidine enhances radial maze performance in rats with modulation of brain amino acid levels. Life Sci. 62:1998;989-994.
47. Schneider C., Risser D., Kirchner L., Kitzmuller E., Cairns N., Prast H., Singewald N., Lubec G. Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease. Neurosci. Lett. 222:1997;183-186.
48. Schwartz J.C., Arrang J.M., Garbarg M., Pollard H., Ruat M. Histaminergic transmission in the mammalian brain. Physiol Rev. 71:1991;1-51.
49. Spinks T.J., Guzzardi R., Bellina C.R. Performance characteristics of a whole body positron tomograph. J. Nucl. Med. 29:1988;1833-1841.
50. Talairach J., Tournoux P. A Co-Planar Stereotaxic Atlas of the Human Brain. 1988;Thieme, Stuttgart.
51. Volkow N.D., Fowler J.S., Gatley S.J., Logan J., Wang G.J., Ding Y.S., Dewey S. PET evaluation of the dopamine system of the human brain. J. nucl. Med. 37:1996;1242-1256.
52. Volkow N.D., Rosen B., Farde L. Imaging the living human brain: magnetic resonance imaging and positron emission tomography. Proc. natn. Acad. Sci. USA. 94:1997;2787-2788.
53. Vorobjev V.S., Shaonova I.N., Walsh I.B., Haas H. Histamine potentiates N-methyl-D-aspartate responses in acutely isolated hippocampal neurons. Neuron. 11:1993;837-844.
54. Watanabe T., Taguchi Y., Shiosaka S., Tanaka J., Kubota H., Terano Y., Tohyama M., Wada H. Distribution of the histaminergic neuron system in the central nervous system of rats: a fluorescent immunohistochemical analysis with histidine decarboxylase as a marker. Brain Res. 295:1984;13-25.
55. Watanabe T. and Wada H. (1991) In Histamine Neurons: Morphology and Function (eds Watanabe T. and Wada H.). CRC, Boca Raton, FL.
56. Yanai K., Son L.Z., Endou M., Sakurai E., Nakagawasai O., Tadano T., Kisara K., Inoue I., Watanabe T., Watanabe T. Behavioral characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H1 receptors. Neuroscience. 87:1998;479-487.
57. Yanai K., Watanabe T., Meguro K., Yokoyama H., Sato I., Sasano H., Itoh M., Iwata R., Takahashi T., Ido T. Age-dependent decrease in histamine H1 receptor in human brains revealed by PET. NeuroReport. 3:1992;433-436.
58. 11C]doxepin and positron emission tomography. Neurosci. Lett. 137:1992;145-148.